Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns Vermillion of Noncompliance for Low Bid Price

NEW YORK (GenomeWeb News) – Vermillion said that it has received a non-compliance warning letter from the Nasdaq Stock Market because it has failed to maintain a minimum bid price of $1 over the past 30 business days.
Vermillion was previously called Ciphergen. Trading opened for the company under the symbol "VMRL" on August 27, when it was trading at just over $.80 a share.
The stock's value ticked up to $.93 a share two days later, after Vermillion published a study showing how a protein biomarker it had developed may help to diagnose peripheral artery disease.
Nasdaq has given the company an initial period of 180 calendar days, or until March 4, 2008, to trade above the $1 minimum listing price for 10 or more consecutive business days.
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.